HYSEQ oder die Aktie die sich nicht bewegt - 500 Beiträge pro Seite
eröffnet am 18.09.00 17:02:50 von
neuester Beitrag 15.02.01 14:13:21 von
neuester Beitrag 15.02.01 14:13:21 von
Beiträge: 14
ID: 245.806
ID: 245.806
Aufrufe heute: 0
Gesamt: 943
Gesamt: 943
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| 19.06.11, 13:50 | 173 | |
| gestern 12:46 | 110 | |
| gestern 21:35 | 103 | |
| 02.07.09, 11:22 | 97 | |
| 21.02.13, 13:43 | 81 | |
| 24.01.14, 16:47 | 80 | |
| vor 1 Stunde | 79 | |
| gestern 23:06 | 64 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 17.749,00 | -0,14 | 172 | |||
| 2. | 2. | 149,93 | -3,55 | 121 | |||
| 3. | 3. | 7,0000 | -5,41 | 78 | |||
| 4. | 7. | 6,7290 | +2,08 | 58 | |||
| 5. | 6. | 6,6100 | +7,48 | 57 | |||
| 6. | 4. | 2.378,67 | 0,00 | 55 | |||
| 7. | 5. | 0,1845 | -8,21 | 54 | |||
| 8. | 8. | 3,7400 | +3,82 | 51 |
Feedback
Hallo zusammen
nachdem hier alles eingeschlafen ist wollte ich mal nen neuen thread zu hyseq aufmachen
der kursverlauf ist momentan ja alles andere als spannend
jedoch muß ich sagen sie halten sich doch im vergleich zu meinen anderen eher spekulativen
investments sehr gut
würde mal sagen das wenn die 40 $ hürde gepackt ist schnell aufwärts geht aber leider ist das umfeld
derzeit äußerst mies
hoffe das sich ein paar finden die auch noch interesse haben über hyseq zu quatschen
grüsse
K.
nachdem hier alles eingeschlafen ist wollte ich mal nen neuen thread zu hyseq aufmachen
der kursverlauf ist momentan ja alles andere als spannend
jedoch muß ich sagen sie halten sich doch im vergleich zu meinen anderen eher spekulativen
investments sehr gut
würde mal sagen das wenn die 40 $ hürde gepackt ist schnell aufwärts geht aber leider ist das umfeld
derzeit äußerst mies
hoffe das sich ein paar finden die auch noch interesse haben über hyseq zu quatschen
grüsse
K.
hallo
dann sind wir je jetzt 2 , die in hysec investiert haben .
ich habe bei 53,-- gekauft
und sie bewegt sich und zwar nach unten , wir hatten zwar schon ein kleines zwischenhof bei 48 ,-- aber jetzt halten wir uns wohl bei 40
sehr schön
auf bessere zeiten !!
dann sind wir je jetzt 2 , die in hysec investiert haben .
ich habe bei 53,-- gekauft
und sie bewegt sich und zwar nach unten , wir hatten zwar schon ein kleines zwischenhof bei 48 ,-- aber jetzt halten wir uns wohl bei 40
sehr schön
auf bessere zeiten !!
Bin bei 39,90 Euro eingestiegen. Top Aktie. Nur Gedult. Siehe Chart vom Fr.Bis kurz vor 22:00 im - mit 2,5%, dann über 5% im +. Hat ein Großinvestor gekauft VERY GOOOOOOD!!!!!!!!
sind ja kaum noch umsätze bei der aktie auszumachen in amerika
also wenn nur irgendwer anfängt zu kaufen müßten doch 20 % oder mehr einmal drinnen sein
also lasst was hören
werdenb doch noch mehr leute in hysq investiert sein
K.
also wenn nur irgendwer anfängt zu kaufen müßten doch 20 % oder mehr einmal drinnen sein
also lasst was hören
werdenb doch noch mehr leute in hysq investiert sein
K.
bin auch mit von der partie bei HYSQ und halte diesen wert für das beste, was der BioChip-Sektor zu bieten hat. Kürzlich habe ich zum vergleich mit AFFX mal etwas in folgendem Thread: Ist Affymetrix oder Hyseq das .......
gepostet.
Gruß
fc
gepostet.
Gruß
fc
Trading Spotlight
Hallo zusammen
heute sollen zahlen zu hyseq kommen hat jemand eine ahnung wie die aussehen sollen
kommen allerdings erst nach boersenschluss
grüsse
K.
heute sollen zahlen zu hyseq kommen hat jemand eine ahnung wie die aussehen sollen
kommen allerdings erst nach boersenschluss
grüsse
K.
hier ist das Q ergebnis
Thursday October 26, 8:55 am Eastern Time
Press Release
SOURCE: Hyseq, Inc.
Hyseq Announces Third Quarter Results
SUNNYVALE, Calif., Oct. 26 /PRNewswire/ -- Hyseq, Inc. (Nasdaq: HYSQ - news) today announced its financial results for
the third quarter and nine-month periods ended September 30, 2000. For the quarter ended September 30, 2000, Hyseq
reported revenues of $5.9 million and a net loss of $4.1 million, or $0.30 per share. This result compared to revenues of $1.5 million and a net loss of $4.3 million,
or $0.33 per share, for the same period of 1999. ``This increase in revenue was primarily attributable to reaching full capacity in our agriculture-based gene
discovery collaboration with American Cyanamid Company, a subsidiary of BASF,`` said Mr. Mark Gitter, Hyseq`s Chief Financial Officer. ``We look forward to
continuing this relationship for the more than two and one half years remaining in our agreement,`` he stated.
For the nine months ended September 30, 2000, Hyseq reported revenues of $11.3 million and a net loss of $15.6 million, or $1.16 per share. This result compared
to revenues of $5.3 million and a net loss of $13.5 million, or $1.04 per share, for the same period of 1999. Revenues during the first nine months of 2000 increased
primarily as a result of our collaboration with American Cyanamid, the completion of the third year of Hyseq`s collaboration with Chiron Corporation which ended
May 31, 2000 and Chiron`s extension of its collaboration with the Company for two additional years starting on June 1, 2000 pursuant to which Chiron pays a
minimum fee of $1.0 million per year. Revenue during the first nine months of 1999 included $1.2 million under our collaboration with Kirin Pharmaceuticals, a
division of Kirin Brewery Co. Ltd of Japan.
Operating expenses increased in the three and nine month periods primarily due to increased personnel and supply costs related to the Company`s collaborations,
expansion of its gene discovery and complete gene sequencing programs, development of its biopharmaceutical product candidates, costs related to expansion and
enforcement of Hyseq`s intellectual property rights, and the addition of new leased space for laboratory and office expansion during the third quarter which is
expected to be occupied during 2001.
As of September 30, 2000, the Company had $13.3 million of cash, cash equivalents, and short-term investments, compared to $30.6 million, at December 31,
1999. The decrease in cash and short-term investments resulted from an increase in the Company`s ongoing operating expenses, further laboratory and office
build-out at our current facilities, and capital equipment purchases.
At the end of September there were approximately 13.7 million shares of Hyseq common stock outstanding.
During the third quarter, Hyseq entered into a consortium with MSI`s Functional Genomics Consortium. As a founding member, Hyseq has utilized high throughput
gene annotation software from MSI, a subsidiary of Pharmacopeia, and will assist in the direction of development of software by the Consortium. This set of
algorithms has allowed the prediction of protein structure and thus the assignment of function for several novel genes from Hyseq`s database, streamlining and
accelerating the pipeline for discovery and development of new biopharmaceutical drug products.
Hyseq is researching and developing biopharmaceuticals to treat acute and chronic diseases. Hyseq uses its high-throughput proprietary technology for discovering
and developing therapeutic product candidates and for pharmacogenomic and polymorphism analysis. Hyseq has collaborations for discovering gene-based
products and for commercializing its HyChip(TM) biochip. Information about Hyseq is available at www.hyseq.com or by phoning (408) 524-8100.
Statements included in this press release which are not historical in nature are intended to be, and are hereby identified as, ``forward-looking statements`` for
purposes of the safe harbor provided by the Private Securities Litigation Act of 1995. Forward-looking statements may be identified by words such as ``believe,``
``expect,`` ``anticipate,`` ``should,`` ``may,`` ``estimates,`` ``potential,`` among others. The Company cautions readers that forward-looking statements, including
without limitation, those relating to the Company`s future business prospects are subject to certain risks and uncertainties that could cause actual results to differ
materially from those indicated in the forward-looking statements. For a discussion of factors that may cause results to differ, including but not limited to gene-based
commercialization, collaborative arrangements, fluctuations in operating results, patents and proprietary information, certain litigation and need for additional funding,
see the Company`s reports filed with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 1999. Hyseq disclaims any intent or
obligation to update these forward-looking statements.
HYSEQ, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands)
(Unaudited)
Three months ended Nine months ended
September 30 September 30
2000 1999 2000 1999
Contract revenues $5,936 $1,490 11,315 $5,285
Operating expense:
Research and
development 7,910 4,389 20,122 14,143
General and
administrative 2,225 1,757 7,296 5,718
Total operating
expenses 10,135 6,146 27,418 19,861
Loss from operations (4,199) (4,656) (16,103) (14,576)
Interest income
(expense), net 83 324 545 1,108
Net loss $(4,116) $(4,332) $(15,558) $(13,468)
Basic and diluted net
loss per share $(0.30) $(0.33) $(1.16) $(1.04)
Shares used in computing
basic and diluted net
loss per share 13,616 13,016 13,369 12,993
CONDENSED CONSOLIDATED BALANCE SHEET
AND OTHER DATA
(in thousands)
September 30, December 31,
2000 1999*
(unaudited)
Cash, cash equivalents and
short-term investments $13,313 $30,637
Accounts receivable 115 1,250
Working capital 4,665 22,077
Cash on deposit 2,106 2,106
Total assets 31,227 45,364
Deferred revenue 4,409 5,000
Noncurrent portion of capital
lease and loan obligations 5,333 5,221
Accumulated deficit (65,227) (49,669)
Total stockholders` equity 14,598 29,222
The condensed consolidated balance sheet data at December 31, 1999 has been derived from the audited financial statements as of that date.
Contact:
Mark E. Gitter
Chief Financial Officer
Hyseq, Inc.
408-524-8100
Dawn Nakao
Investor Relations Manager
Hyseq, Inc.
408-524-8100
Lee Stern (Investors)
The Trout Group
212-477-9007
Robert Gottlieb (Media)
Feinstein Kean Healthcare
617-577-8110
SOURCE: Hyseq, Inc.
Email this story - View most popular stories emailed
More Quotes and News:
Hyseq Inc (NasdaqNM:HYSQ - news)
Related News Categories: banking, biotech, earnings, medical/pharmaceutical
grüsse
K.
Thursday October 26, 8:55 am Eastern Time
Press Release
SOURCE: Hyseq, Inc.
Hyseq Announces Third Quarter Results
SUNNYVALE, Calif., Oct. 26 /PRNewswire/ -- Hyseq, Inc. (Nasdaq: HYSQ - news) today announced its financial results for
the third quarter and nine-month periods ended September 30, 2000. For the quarter ended September 30, 2000, Hyseq
reported revenues of $5.9 million and a net loss of $4.1 million, or $0.30 per share. This result compared to revenues of $1.5 million and a net loss of $4.3 million,
or $0.33 per share, for the same period of 1999. ``This increase in revenue was primarily attributable to reaching full capacity in our agriculture-based gene
discovery collaboration with American Cyanamid Company, a subsidiary of BASF,`` said Mr. Mark Gitter, Hyseq`s Chief Financial Officer. ``We look forward to
continuing this relationship for the more than two and one half years remaining in our agreement,`` he stated.
For the nine months ended September 30, 2000, Hyseq reported revenues of $11.3 million and a net loss of $15.6 million, or $1.16 per share. This result compared
to revenues of $5.3 million and a net loss of $13.5 million, or $1.04 per share, for the same period of 1999. Revenues during the first nine months of 2000 increased
primarily as a result of our collaboration with American Cyanamid, the completion of the third year of Hyseq`s collaboration with Chiron Corporation which ended
May 31, 2000 and Chiron`s extension of its collaboration with the Company for two additional years starting on June 1, 2000 pursuant to which Chiron pays a
minimum fee of $1.0 million per year. Revenue during the first nine months of 1999 included $1.2 million under our collaboration with Kirin Pharmaceuticals, a
division of Kirin Brewery Co. Ltd of Japan.
Operating expenses increased in the three and nine month periods primarily due to increased personnel and supply costs related to the Company`s collaborations,
expansion of its gene discovery and complete gene sequencing programs, development of its biopharmaceutical product candidates, costs related to expansion and
enforcement of Hyseq`s intellectual property rights, and the addition of new leased space for laboratory and office expansion during the third quarter which is
expected to be occupied during 2001.
As of September 30, 2000, the Company had $13.3 million of cash, cash equivalents, and short-term investments, compared to $30.6 million, at December 31,
1999. The decrease in cash and short-term investments resulted from an increase in the Company`s ongoing operating expenses, further laboratory and office
build-out at our current facilities, and capital equipment purchases.
At the end of September there were approximately 13.7 million shares of Hyseq common stock outstanding.
During the third quarter, Hyseq entered into a consortium with MSI`s Functional Genomics Consortium. As a founding member, Hyseq has utilized high throughput
gene annotation software from MSI, a subsidiary of Pharmacopeia, and will assist in the direction of development of software by the Consortium. This set of
algorithms has allowed the prediction of protein structure and thus the assignment of function for several novel genes from Hyseq`s database, streamlining and
accelerating the pipeline for discovery and development of new biopharmaceutical drug products.
Hyseq is researching and developing biopharmaceuticals to treat acute and chronic diseases. Hyseq uses its high-throughput proprietary technology for discovering
and developing therapeutic product candidates and for pharmacogenomic and polymorphism analysis. Hyseq has collaborations for discovering gene-based
products and for commercializing its HyChip(TM) biochip. Information about Hyseq is available at www.hyseq.com or by phoning (408) 524-8100.
Statements included in this press release which are not historical in nature are intended to be, and are hereby identified as, ``forward-looking statements`` for
purposes of the safe harbor provided by the Private Securities Litigation Act of 1995. Forward-looking statements may be identified by words such as ``believe,``
``expect,`` ``anticipate,`` ``should,`` ``may,`` ``estimates,`` ``potential,`` among others. The Company cautions readers that forward-looking statements, including
without limitation, those relating to the Company`s future business prospects are subject to certain risks and uncertainties that could cause actual results to differ
materially from those indicated in the forward-looking statements. For a discussion of factors that may cause results to differ, including but not limited to gene-based
commercialization, collaborative arrangements, fluctuations in operating results, patents and proprietary information, certain litigation and need for additional funding,
see the Company`s reports filed with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 1999. Hyseq disclaims any intent or
obligation to update these forward-looking statements.
HYSEQ, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands)
(Unaudited)
Three months ended Nine months ended
September 30 September 30
2000 1999 2000 1999
Contract revenues $5,936 $1,490 11,315 $5,285
Operating expense:
Research and
development 7,910 4,389 20,122 14,143
General and
administrative 2,225 1,757 7,296 5,718
Total operating
expenses 10,135 6,146 27,418 19,861
Loss from operations (4,199) (4,656) (16,103) (14,576)
Interest income
(expense), net 83 324 545 1,108
Net loss $(4,116) $(4,332) $(15,558) $(13,468)
Basic and diluted net
loss per share $(0.30) $(0.33) $(1.16) $(1.04)
Shares used in computing
basic and diluted net
loss per share 13,616 13,016 13,369 12,993
CONDENSED CONSOLIDATED BALANCE SHEET
AND OTHER DATA
(in thousands)
September 30, December 31,
2000 1999*
(unaudited)
Cash, cash equivalents and
short-term investments $13,313 $30,637
Accounts receivable 115 1,250
Working capital 4,665 22,077
Cash on deposit 2,106 2,106
Total assets 31,227 45,364
Deferred revenue 4,409 5,000
Noncurrent portion of capital
lease and loan obligations 5,333 5,221
Accumulated deficit (65,227) (49,669)
Total stockholders` equity 14,598 29,222
The condensed consolidated balance sheet data at December 31, 1999 has been derived from the audited financial statements as of that date.
Contact:
Mark E. Gitter
Chief Financial Officer
Hyseq, Inc.
408-524-8100
Dawn Nakao
Investor Relations Manager
Hyseq, Inc.
408-524-8100
Lee Stern (Investors)
The Trout Group
212-477-9007
Robert Gottlieb (Media)
Feinstein Kean Healthcare
617-577-8110
SOURCE: Hyseq, Inc.
Email this story - View most popular stories emailed
More Quotes and News:
Hyseq Inc (NasdaqNM:HYSQ - news)
Related News Categories: banking, biotech, earnings, medical/pharmaceutical
grüsse
K.
??? :cry ???
ist das hier wie bei den anderen "spekulativen" aktien auch ??
kaum das der wert WIRKLICH spekulativ wird fehlt auch schon das interesse !
ich kann zwar NICHTS zu diesem wert beitragen, lese aber immer wieder gerne solche "gerüchte" um mehr
zu erfahren !
also, wenn es noch "spekulanten" gibt die diesen wert empfehlen können und somit mehr als nur "mögliche gewinne"
vorzuzeigen haben, dann schreibt doch mal wieder einige beiträge über die man dann "lachen" kann !
luckyfinder der auf der suche ist !
ist das hier wie bei den anderen "spekulativen" aktien auch ??
kaum das der wert WIRKLICH spekulativ wird fehlt auch schon das interesse !
ich kann zwar NICHTS zu diesem wert beitragen, lese aber immer wieder gerne solche "gerüchte" um mehr
zu erfahren !
also, wenn es noch "spekulanten" gibt die diesen wert empfehlen können und somit mehr als nur "mögliche gewinne"
vorzuzeigen haben, dann schreibt doch mal wieder einige beiträge über die man dann "lachen" kann !
luckyfinder der auf der suche ist !
hi zusammen
viel neues als das der kurs zum grausen ist gibt es nicht zu berichten
also ist noch irgendwer dabei oder hat jemand vielleicht mal
ne nachricht bezüglich hysq gefunden
grüsse
K.
viel neues als das der kurs zum grausen ist gibt es nicht zu berichten
also ist noch irgendwer dabei oder hat jemand vielleicht mal
ne nachricht bezüglich hysq gefunden
grüsse
K.
Hi! An Alle Hyseqaktionäre!!
Hat das traurige Spiel nun ein Ende gefunden??
Ich denke ja. Die Aktie hat alleine aus dem Grund, daß Hyseq
nicht nur Genchips entwickelt, sondern auch noch an eigene Präperate forscht und hoffentlich auch auf den Markt bringen wird, noch sehr sehr viel Potential.
Ich denke die kleine Ralley der letzten Tage war erst der Anfang und wir werden bald wieder in "alte" Kursregionen vordringen.
Hat das traurige Spiel nun ein Ende gefunden??
Ich denke ja. Die Aktie hat alleine aus dem Grund, daß Hyseq
nicht nur Genchips entwickelt, sondern auch noch an eigene Präperate forscht und hoffentlich auch auf den Markt bringen wird, noch sehr sehr viel Potential.
Ich denke die kleine Ralley der letzten Tage war erst der Anfang und wir werden bald wieder in "alte" Kursregionen vordringen.
Schaut es euch mal an: www.brokerstalk.de.vu
Schaut es euch mal an: www.brokerstalk.de.vu
hallo
vielleicht der ausschlaggebende punkt für wieder steigende
kurse
Thursday January 25, 8:29 am Eastern Time
Press Release
SOURCE: Hyseq, Inc.
Hyseq Announces Markman Decision in Litigation Brought by Affymetrix
Ruling Supports Hyseq`s Defenses
SUNNYVALE, Calif., Jan. 25 /PRNewswire/ -- Hyseq, Inc. (Nasdaq: HYSQ - news) announced today that District Court Judge Jeremy Fogel of the U.S. District
Court for the Northern District of California has issued a Markman order in the litigation brought by Affymetrix against Hyseq. A Markman order is a procedural
step for framing the claims at issue in a patent litigation that occurs before the parties can move for summary judgment. Hyseq believes it is now in a position to seek
a ruling on non-infringement of each of Affymetrix` asserted patents.
``We have always believed that Affymetrix` allegations are without merit, and we intend to vigorously defend against this litigation. We believe that this ruling supports
our position that we do not infringe any valid and enforceable claims of the asserted patents and we are looking forward to seeking a ruling to that effect,`` said Dr.
George Rathmann, Hyseq`s Chairman and CEO.
On August 18, 1998, Affymetrix filed suit against Hyseq in the U.S. District Court for the Northern District of California, San Francisco Division, alleging that Hyseq
infringed Affymetrix`s U.S. Patent Nos. 5,795,716 and 5,744,305. Affymetrix filed an amended complaint on September 1, 1998 alleging infringement of its U.S.
Patent No. 5,800,992. The case was subsequently reassigned to Judge Fogel in the San Jose Division. The Court held a claim construction hearing on November 29
and 30, 2000 and issued the Markman order on January 22, 2001. In its order, the Court requested additional briefings on one claim term.
Hyseq is researching and developing biopharmaceutical products from its collection of novel genes discovered using its proprietary high-throughput technology.
Hyseq has collaborations for discovering gene-based products and for commercializing its HyChip(TM) biochip. Information about Hyseq is available at
www.hyseq.com or by phoning (408) 524-8100.
Contact:
Dawn Nakao
Investor Relations Manager
Hyseq, Inc.
408-524-8100
Lee Stern (Investors)
The Trout Group
212-477-9007
Robert Gottlieb (Media)
Feinstein Kean Healthcare
617-577-8110
SOURCE: Hyseq, Inc.
grüsse
K.
vielleicht der ausschlaggebende punkt für wieder steigende
kurse
Thursday January 25, 8:29 am Eastern Time
Press Release
SOURCE: Hyseq, Inc.
Hyseq Announces Markman Decision in Litigation Brought by Affymetrix
Ruling Supports Hyseq`s Defenses
SUNNYVALE, Calif., Jan. 25 /PRNewswire/ -- Hyseq, Inc. (Nasdaq: HYSQ - news) announced today that District Court Judge Jeremy Fogel of the U.S. District
Court for the Northern District of California has issued a Markman order in the litigation brought by Affymetrix against Hyseq. A Markman order is a procedural
step for framing the claims at issue in a patent litigation that occurs before the parties can move for summary judgment. Hyseq believes it is now in a position to seek
a ruling on non-infringement of each of Affymetrix` asserted patents.
``We have always believed that Affymetrix` allegations are without merit, and we intend to vigorously defend against this litigation. We believe that this ruling supports
our position that we do not infringe any valid and enforceable claims of the asserted patents and we are looking forward to seeking a ruling to that effect,`` said Dr.
George Rathmann, Hyseq`s Chairman and CEO.
On August 18, 1998, Affymetrix filed suit against Hyseq in the U.S. District Court for the Northern District of California, San Francisco Division, alleging that Hyseq
infringed Affymetrix`s U.S. Patent Nos. 5,795,716 and 5,744,305. Affymetrix filed an amended complaint on September 1, 1998 alleging infringement of its U.S.
Patent No. 5,800,992. The case was subsequently reassigned to Judge Fogel in the San Jose Division. The Court held a claim construction hearing on November 29
and 30, 2000 and issued the Markman order on January 22, 2001. In its order, the Court requested additional briefings on one claim term.
Hyseq is researching and developing biopharmaceutical products from its collection of novel genes discovered using its proprietary high-throughput technology.
Hyseq has collaborations for discovering gene-based products and for commercializing its HyChip(TM) biochip. Information about Hyseq is available at
www.hyseq.com or by phoning (408) 524-8100.
Contact:
Dawn Nakao
Investor Relations Manager
Hyseq, Inc.
408-524-8100
Lee Stern (Investors)
The Trout Group
212-477-9007
Robert Gottlieb (Media)
Feinstein Kean Healthcare
617-577-8110
SOURCE: Hyseq, Inc.
grüsse
K.
hier sind die Infos alle nach Hause gegangen.
Die Firma ist doch nicht tot oder?
Die Firma ist doch nicht tot oder?
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 172 | ||
| 121 | ||
| 78 | ||
| 58 | ||
| 57 | ||
| 55 | ||
| 54 | ||
| 51 | ||
| 44 | ||
| 40 |
| Wertpapier | Beiträge | |
|---|---|---|
| 38 | ||
| 31 | ||
| 30 | ||
| 28 | ||
| 27 | ||
| 27 | ||
| 26 | ||
| 23 | ||
| 22 | ||
| 20 |
